Specific binding sites for epidermal growth factor and its effect on human chorionic gonadotrophin secretion by cultured tumour cell lines: comparison between trophoblastic and non-trophoblastic cells

1982 ◽  
Vol 101 (2) ◽  
pp. 281-286 ◽  
Author(s):  
Yukio Hirata ◽  
Satoru Sueoka ◽  
Masahito Uchihashi ◽  
Yoshio Yoshimoto ◽  
Takuo Fujita ◽  
...  
Keyword(s):  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Cell Lines ◽  
Binding Sites ◽  
Specific Binding ◽  
Chorionic Gonadotrophin ◽  
Human Chorionic Gonadotrophin ◽  
Specific Binding Sites ◽  
Epidermal Growth ◽  
Tumour Cell Lines

Abstract. Using human trophoblastic (SCH) and non-trophoblastic (HeLa S3) tumour cell lines, specific binding sites for epidermal growth factor (EGF), a potent stimulator of growth in many tissues, and its effect on secretion of human chorionic gonadotrophin (hCG) and/ or its subunits were compared between these two tumour cells. Both SCH and HeLa S3 cells possessed two populations of specific binding sites for 125I-labelled EGF: the high affinity (Kd ∼10−10m) and the low affinity (Kd ∼ 7 × 10−10 m) system. Tetradecanoyl phorbol acetate (TPA), a tumour promotor, showed a potent competitor of labelled tracer binding to its receptor sites in both cell lines. EGF stimulated both hCG-α and hCG and/or hCG-β secretion in a dose-responsive manner from SCH cells, whereas it had no effect on hCG-α secretion from HeLa S3 cells. In contrast, dibutyryl cyclic AMP plus theophylline, a phosphodiesterase inhibitor, enhanced hCG-α secretion from both cells, while TPA had no effect in either cells. These data suggest that EGF may play a physiological role in hCG secretion from trophoblastic tissues and that the mechanism by which hCG and/or its subunits are secreted may differ between trophoblastic and non-trophoblastic tumour cells.

Specific receptors for epidermal growth factor in human bone tumour cells and its effect on synthesis of prostaglandin E2 by cultured osteosarcoma cell line

1984 ◽  
Vol 107 (1) ◽  
pp. 125-130 ◽  
Author(s):  
Yukio Hirata ◽  
Masahito Uchihashi ◽  
Hiroko Nakashima ◽  
Takuo Fujita ◽  
Shigeru Matsukura ◽  
...  
Keyword(s):  
Growth Factor ◽  
Cell Lines ◽  
Binding Sites ◽  
Specific Binding ◽  
Bone Tumour ◽  
Human Bone ◽  
Osteosarcoma Cell ◽  
Specific Binding Sites ◽  
Epidermal Growth ◽  
Tumour Cell Lines

Abstract. Using tumour cell lines derived from human bone tumours, specific binding sites for epidermal growth factor (EGF), a potent growth stimulator in many tissues, and its effect on synthesis of prostaglandin (PG) E2, a potent bone-resorbing factor, by cultured osteosarcoma cell line were studied. Three tumour cell lines, one osteosarcoma (HOSO) and two giant cell tumours of the bone (G-1 and G-2), all possessed specific binding sites for 125I-labelled EGF: the apparent dissociation constant was ~4–10 × 10−10 m and the maximal binding capacity was 50 000–80 000 sites/cell. EGF had no mitogenic effect in these cell lines. However, these cell lines did not have specific binding sites for 125I-labelled parathyroid hormone (PTH) or calcitonin. HOSO line produced and secreted PGE2 into medium, while no significant amount of PGE2 was demonstrated in G-1 or G-2 line. EGF significantly stimulated PGE2 production in HOSO line in a dose-dependent manner (0.5–50 ng/ml); its stimulatory effect was completely abolished by indomethacin, an inhibitor of PG biosynthesis. Exogenous PGE1 significantly stimulated cyclic AMP formation in HOSO line, whereas PGF2α, PTH, calcitonin, or EGF had no effect. None of these calcium-regulating hormones affected cyclic AMP generation in either G-1 or G-2 line. These data indicate that human bone tumour cells have specific EGF receptors unrelated to cell growth, and suggest that EGF may be involved in bone resorption through a PGE2-mediated process in human osseous tissues.

scholarly journals Characteristics of specific binding of epidermal growth factor (EGF) on human tumor cell lines.

1983 ◽  
Vol 30 (5) ◽  
pp. 601-607 ◽  
Author(s):  
YUKIO HIRATA ◽  
MASAHITO UCHIHASHI ◽  
TAKUO FUJITA ◽  
SHIGERU MATSUKURA ◽  
TEIICHI MOTOYAMA ◽  
...  
Keyword(s):  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Tumor Cell ◽  
Cell Lines ◽  
Specific Binding ◽  
Human Tumor ◽  
Tumor Cell Lines ◽  
Human Tumor Cell ◽  
Human Tumor Cell Lines ◽  
Epidermal Growth

scholarly journals Intrauterine Infusion of Autologous Platelet-Rich Plasma Affects the Endometrial Thickness, Epidermal Growth Factor and Pregnancy Outcome in Patients Undergoing IUI

2020 ◽  
Vol 9 (2) ◽  
Author(s):  
Wafaa A. Abaid ◽  
◽  
Manal T. Al-Obaidi ◽  
Muayad S. Abood ◽  
◽  
...  
Keyword(s):  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Endometrial Thickness ◽  
Platelet Rich Plasma ◽  
Chorionic Gonadotrophin ◽  
Human Chorionic Gonadotrophin ◽  
Epidermal Growth ◽  
Autologous Platelet Rich Plasma ◽  
The Mean ◽  
Autologous Platelet

Despite developments in assisted reproductive technology, there is immaterial progress in the implantation and pregnancy rates. Intrauterine infusion (IUIF) of autologous platelet-rich plasma (PRP) might renew implantation rates through its paracrine properties by progression cytokines and growth factors which favor implantation. Here we determine whether the IUIF of autologous PRP had a role in pregnancy outcome through its outcome on epidermal growth factor and endometrial thickness. An overall of 43 patients where prospectively randomly dispersed into two groups subjected to a superovulation program using Letrozole® tablet orally 2.5 mg twice daily 12 hours apart from day 2 for 5 days for one cycle. 20 women were considered as control receiving the conventional intrauterine insemination (IUI) management while 23 of them were given PRP by IUIF on the day of human chorionic gonadotrophin injection. The IUI was done for both groups 36-48 hours after confirming ovulation. The blood samples were collected from both groups on the day of IUI for the valuation of epidermal growth factor and an ultrasound was done on the day of human chorionic gonadotrophin injection and day of IUI for assessment of endometrial thickness. The mean endometrial thickness in the PRP group at the day of IUI was significantly thicker than that of the control group and the difference in percentage change of endometrial thickness between PRP group and controls significantly higher in PRP group. The mean epidermal growth factor and the pregnancy rate were significantly superior in the PRP group than that of controls. In conclusion, autologous PRP IUIF was well-tolerated and resulted in a significant expansion in endometrial thickness, epidermal growth factor Level and, subsequent pregnancy rate in an infertile woman undergoing IUI.

scholarly journals A dual immunocytochemical assay for oestrogen and epidermal growth factor receptors in tumour cell lines

1994 ◽  
Vol 26 (4) ◽  
pp. 306-310 ◽  
Author(s):  
A. K. Sharma ◽  
K. Horgan ◽  
R. A. McClelland ◽  
A. G. Douglas-Jones ◽  
T. Van Agthoven ◽  
...  
Keyword(s):  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Cell Lines ◽  
Tumour Cell ◽  
Growth Factor Receptors ◽  
Epidermal Growth Factor Receptors ◽  
Immunocytochemical Assay ◽  
Epidermal Growth ◽  
Tumour Cell Lines

scholarly journals Distribution of mRNA for human epiregulin, a differentially expressed member of the epidermal growth factor family

1997 ◽  
Vol 326 (1) ◽  
pp. 69-75 ◽  
Author(s):  
Hitoshi TOYODA ◽  
Toshi KOMURASAKI ◽  
Daisuke UCHIDA ◽  
Sigeo MORIMOTO
Keyword(s):  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Cell Lines ◽  
Tumour Cell ◽  
Biologically Active ◽  
Soluble Form ◽  
Egf Receptors ◽  
Epidermal Growth ◽  
Tumour Cell Lines ◽  
Egf Family

We have recently identified epiregulin as a new growth regulator and a member of the epidermal growth factor (EGF) family. Epiregulin has certain characteristics that are different from those of the classical members of the EGF family, EGF and transforming growth factor α, including mitogenic responses on several normal cells and binding to EGF receptors on epidermoid carcinoma A431 cells. In the present study we cloned and identified the expression of human epiregulin transcript. The human epiregulin gene encoded a 163-residue putative transmembrane precursor containing an EGF-like domain in the internal segment, and the structural organization was similar to that of other members of the EGF family that bind to EGF receptors. Northern blot analysis showed the expression of human epiregulin to be mainly on peripheral blood macrophages and the placenta in normal tissues, and was highest on epithelial tumour cell lines in various types of tumour cell lines. The expression profile was quite different from that of other members of the EGF family in normal and tumour cells. Recombinant expression in mammalian cells also showed that human epiregulin was secreted as a soluble form of approx. 5 kDa that is biologically active on the basis of the stimulation of DNA synthesis. Our findings suggest that epiregulin is involved in certain physiological processes such as maintenance or development of normal cell growth, and the progression of carcinomas.

Sign in / Sign up

Export Citation Format

Share Document